Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: GlobeNewswire
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics (LRMR) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $12.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]Seeking Alpha
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
LRMR
Earnings
- 3/19/26 - Miss
LRMR
Sec Filings
- 4/10/26 - Form PRE
- 3/19/26 - Form S-8
- 3/19/26 - Form 10-K
- LRMR's page on the SEC website